Helsinn is a privately owned self-financing pharmaceutical Group founded in 1976, headquartered in Lugano, Switzerland, now with a total of more than 550 employees.
Helsinn’s business strategy is to in-license, finance, develop, manufacture, register, distribute and support the commercialization of innovative cancer-care therapies, value-added pharmaceutical products and medical devices to improve cancer patients’ health and quality of life. The large portfolio of marketed products has been sold in more than 90 countries worldwide through over 60 commercial and marketing partners.
The Helsinn business model is supported by an integrated R&D structure based in Lugano and Bridgewater (NJ-US) for preclinical and clinical drug development and registration. Marketing and medical education services complete the support to our partners. The Group has a state-of-the-art chemical plant in Biasca (CH) for the development and manufacturing of APIs, HPAPIs and cytotoxic compounds, also for third parties; a world-class development, production and logistics facility for Drug Products in Dublin (IRL); an expanding presence in the US through the launch in 2013 of an
oncology sales & marketing organization; and a representative office in China since 2012.
Helsinn’s mission is to bring respect, integrity and quality to our products, services, and all that we do to improve the health and quality of life of every person affected by cancer
Via Pian Scairolo 9
|T.: +41 91 985 21 21|
|F.: +41 91 993 21 22|
Attività principali Licensing-In ● Licensing-Out ●
Fasi di sviluppo Pre-clinical ● Phase I - Phase III ● Registration ● Market ● Life cycle management ●
Aree terapeutiche Cancer supportive therapy ● Gastrointestinal ● Metabolism ● Oncology ● Pain ●
Mercati CH ● EU Top 5 ● Rest of Europe ● USA and Canada ● LATAM ● MENA ● BRICS ● ASEAN ● Australia ● Japan ●